Announcements Trials
Browse Landscape

Phase

Phase 2 16Phase 1 8Phase 1/2 3Phase 3 2

Status

Completed 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 45Genitourinary 14Thoracic 4Other hematologic neoplasm 3Tumor-Agnostic 2Sarcoma 2Dermatologic 2Head & Neck 1Breast 1

Conditions

Melanoma 2

Interventions

Dacarbazine 27Nivolumab 26pembrolizumab 22Ipilimumab 203-ingenyl angelate 11Interferon-alpha 10Imiquimod 10Temozolomide 9trametinib 8Vemurafenib 8Photochemotherapy 8Aminolevulinic Acid 8methyl 5-aminolevulinate 7dabrafenib 7cemiplimab 7aldesleukin 7Introns 7Surgical Procedures, Operative 6Radiotherapy 6Interferon alpha-2 6Fluorouracil 6Paclitaxel 5Melphalan 5Interleukin-2 5Cisplatin 5Chemotherapy, Adjuvant 5talimogene laherparepvec 4binimetinib 4Specimen Handling 4Opdualag 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Sorafenib × Dermatologic × Clear all
NCT00110019 2015-10-19

Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 3 Completed
823 enrolled 9 charts
Dermatologic

Melanoma

NCT00111007 2014-10-31

A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma

Bayer

Phase 3 Completed
270 enrolled 15 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡